Drug intelligence / Profile preview

ART003

Development stage: Preclinical
Lead developer: Accuredit Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies

Overview

ART003 is a preclinical-stage *in vivo* gene-editing therapeutic candidate being developed by Accuredit Therapeutics. It is designed to treat an undisclosed hereditary disease that affects an estimated 0.2 to 0.3 million patients worldwide. The program utilizes Accuredit's proprietary gene-editing platform to perform precise genetic modifications directly within the patient's body. As of 2024, the specific molecular target and the exact nature of the hereditary condition remain proprietary and have not been publicly disclosed by the sponsor.

Other names: ART003ART-003ART 003

Beyond the preview

Go deeper on ART003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART003.

Explore the full profile